105 related articles for article (PubMed ID: 12416026)
1. In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts.
Kruczynski A; Ricome C; Waud WR; Hill BT
J Exp Ther Oncol; 2002; 2(4):219-27. PubMed ID: 12416026
[TBL] [Abstract][Full Text] [Related]
2. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103.
Etiévant C; Kruczynski A; Barret JM; Perrin D; van Hille B; Guminski Y; Hill BT
Cancer Chemother Pharmacol; 2000; 46(2):101-13. PubMed ID: 10972479
[TBL] [Abstract][Full Text] [Related]
3. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases.
Kruczynski A; Etiévant C; Perrin D; Imbert T; Colpaert F; Hill BT
Br J Cancer; 2000 Dec; 83(11):1516-24. PubMed ID: 11076662
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
5. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents.
Barret JM; Kruczynski A; Etiévant C; Hill BT
Cancer Chemother Pharmacol; 2002 Jun; 49(6):479-86. PubMed ID: 12107553
[TBL] [Abstract][Full Text] [Related]
8. A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment.
Meier C; Steinhauer TN; Koczian F; Plitzko B; Jarolim K; Girreser U; Braig S; Marko D; Vollmar AM; Clement B
ChemMedChem; 2017 Mar; 12(5):347-352. PubMed ID: 28099785
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine, a novel deoxyadenosine analog, against human colon tumor xenografts by oral administration.
Takahashi T; Kanazawa J; Akinaga S; Tamaoki T; Okabe M
Cancer Chemother Pharmacol; 1999; 43(3):233-40. PubMed ID: 9923554
[TBL] [Abstract][Full Text] [Related]
10. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of KF22678, a novel thioester derivative of leinamycin.
Ashizawa T; Kawashima K; Kanda Y; Gomi K; Okabe M; Ueda K; Tamaoki T
Anticancer Drugs; 1999 Oct; 10(9):829-36. PubMed ID: 10587293
[TBL] [Abstract][Full Text] [Related]
12. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of 4'-thio-beta-D-arabinofuranosylcytosine (4'-thio-ara-C).
Waud WR; Gilbert KS; Shepherd RV; Montgomery JA; Secrist JA
Cancer Chemother Pharmacol; 2003 May; 51(5):422-6. PubMed ID: 12679884
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Houghton PJ; Cheshire PJ; Myers L; Stewart CF; Synold TW; Houghton JA
Cancer Chemother Pharmacol; 1992; 31(3):229-39. PubMed ID: 1464161
[TBL] [Abstract][Full Text] [Related]
18. Novel antitumor indolizino[6,7-b]indoles with multiple modes of action: DNA cross-linking and topoisomerase I and II inhibition.
Chaniyara R; Tala S; Chen CW; Zang X; Kakadiya R; Lin LF; Chen CH; Chien SI; Chou TC; Tsai TH; Lee TC; Shah A; Su TL
J Med Chem; 2013 Feb; 56(4):1544-63. PubMed ID: 23360284
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II.
Etiévant C; Kruczynski A; Barret JM; Perrin D; Hill BT
Biochem Pharmacol; 2003 Mar; 65(5):755-63. PubMed ID: 12628489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
